Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant milestone for Dechra Pharmaceuticals-B (德琪医药-B), enhancing its market presence and competitiveness in the biopharmaceutical sector [1]. Company Summary - Dechra Pharmaceuticals-B's stock rose nearly 6%, with a current price of 4.34 HKD and a trading volume of 9.4944 million HKD [1]. - The approved indications for Selinexor include treatment for multiple myeloma in combination with Bortezomib and Dexamethasone for adult patients who have received at least one prior therapy, and for relapsed or refractory diffuse large B-cell lymphoma as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not candidates for hematopoietic stem cell transplantation [1]. Industry Summary - The approval signifies Dechra Pharmaceuticals-B's ongoing enhancement in research and market promotion capabilities within the biopharmaceutical field [1]. - The introduction of Selinexor is expected to address the treatment needs for relevant diseases in the Hong Kong market, thereby improving the company's competitiveness in the biotechnology industry [1].
港股异动 德琪医药-B(06996)涨近6% 希维奥两项补充新药申请获香港卫生署批准